Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02073812 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects
A Phase 1 study, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company).
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02073812: Completed Phase 1 study, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company).
NCT02073812 is a Phase 1 study that has completed, run by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company). The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02073812, a Phase 1 study, has completed, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
RPX7009(beta-lactamase inhibitor) is being studied in combination with a carbapenem (RPX2014) to treat bacterial infections, including those due to multi-drug resistant bacteria.
Primary Outcome
Assessment of plasma, ELF and AM concentrations of RPX2014 and RPX7009 after 3 doses of Carbavance
Interventions
- DRUG RPX7009 and RPX2014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
What the finished NCT02073812 record still lists
NCT02073812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which RPX7009 and RPX2014 is the first listed.
NCT02073812 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02073812 about?
NCT02073812 is a clinical study titled "Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects". RPX7009(beta-lactamase inhibitor) is being studied in combination with a carbapenem (RPX2014) to treat bacterial infections, including those due to multi-drug resistant bacteria.
What is the current status of trial NCT02073812?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02073812?
The interventions under investigation include: RPX7009 and RPX2014 (DRUG).
Who is sponsoring clinical trial NCT02073812?
This trial is sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02073812's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia